Exceptional diazoxide sensitivity in hyperinsulinaemic hypoglycaemia due to a novel HNF4A mutation

Diazoxide is the first-line treatment for patients with hyperinsulinaemic hypoglycaemia (HH). Approximately 50% of patients with HH are diazoxide resistant. However, marked diazoxide sensitivity resulting in severe hyperglycaemia is extremely uncommon and not reported previously in the context of HH...

Descripción completa

Detalles Bibliográficos
Autores principales: Arya, Ved Bhushan, Kalitsi, Jennifer, Hickey, Ann, Flanagan, Sarah E, Kapoor, Ritika R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2019
Materias:
Unusual Effects of Medical Treatment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528403/
https://www.ncbi.nlm.nih.gov/pubmed/31096182
http://dx.doi.org/10.1530/EDM-19-0013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528403/
https://www.ncbi.nlm.nih.gov/pubmed/31096182
http://dx.doi.org/10.1530/EDM-19-0013

Ejemplares similares